Actually it seems they're already reviewing eteplirsen and the data the requested won't slow down the review. So the harm they did was to the stock short term, not to the kids. In fact, with the additional pages they get from Sarepta, they'll have ammunition to support new drugs developed using the same technology targeting other exons. I think they have the best interests of the kids at heart, and they won't hurt investors in SRPT, but they did cream day traders in SRPT today. Hold and you will be rewarded.